NASDAQ:ABMD - ABIOMED Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$325.61 +10.36 (+3.29 %)
(As of 01/15/2019 04:00 PM ET)
Previous Close$315.25
Today's Range$316.62 - $327.46
52-Week Range$216.00 - $459.75
Volume358,240 shs
Average Volume556,442 shs
Market Capitalization$14.58 billion
P/E Ratio132.90
Dividend YieldN/A
Beta0.38
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Current Ratio6.85
Quick Ratio6.07

Price-To-Earnings

Sales & Book Value

Annual Sales$593.75 million
Price / Sales24.70
Cash Flow$2.7973 per share
Price / Cash Flow116.40
Book Value$15.57 per share
Price / Book20.91

Profitability

Net Income$112.17 million
Net Margins27.60%
Return on Assets17.79%

Miscellaneous

Employees1,143
Market Cap$14.58 billion
OptionableOptionable

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, November, 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.73 by $0.36. The medical equipment provider had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. ABIOMED's revenue for the quarter was up 36.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.54 EPS. View ABIOMED's Earnings History.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, January 31st 2019. View Earnings Estimates for ABIOMED.

What guidance has ABIOMED issued on next quarter's earnings?

ABIOMED issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $780-780 million, compared to the consensus revenue estimate of $773.55 million.ABIOMED also updated its Q3 2019 guidance to EPS.

What price target have analysts set for ABMD?

8 analysts have issued 12-month target prices for ABIOMED's shares. Their forecasts range from $280.00 to $480.00. On average, they anticipate ABIOMED's stock price to reach $391.6250 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for ABIOMED.

What is the consensus analysts' recommendation for ABIOMED?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.

Has ABIOMED been receiving favorable news coverage?

Headlines about ABMD stock have been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ABIOMED earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)
  • Dr. David M. Weber, Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Mr. Ian McLeod, VP & Corp. Controller

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.22%), Retirement Systems of Alabama (0.19%), Navellier & Associates Inc (0.05%), Gulf International Bank UK Ltd (0.02%), Dorsey Wright & Associates (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Which institutional investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Dorsey Wright & Associates, Gulf International Bank UK Ltd, First Hawaiian Bank and Louisiana State Employees Retirement System. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.

Which institutional investors are buying ABIOMED stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, QUANTRES ASSET MANAGEMENT Ltd, Sit Investment Associates Inc., Navellier & Associates Inc, Cerebellum GP LLC, State of Alaska Department of Revenue, Ipswich Investment Management Co. Inc. and Gateway Investment Advisers LLC. View Insider Buying and Selling for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $325.61.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $14.58 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

What is ABIOMED's official website?

The official website for ABIOMED is http://www.abiomed.com.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  425 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  777
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel